Page 12 - Priority Review News Today

Priority Review granted based on positive results from two Phase 3 trials; if approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for

French stocks were little changed on Friday as investors digested hawkish comments from a Federal Reserve official and awaited remarks from European Central Bank policymakers, including President Christine Lagarde for direction.

Priority Review granted based on positive results from two Phase 3 trials; if approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for this disease in...

French drug major Sanofi (SNYNF, SNY) announced Friday that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application or sBLA for Dupixent (dupilumab).

In this article, we will be taking a look at the 20 fastest growing biotech companies in the US. If you are not interested in learning about the landscape of biotech companies, head straight to the 5 Fastest Growing Biotech Companies In The US. The biotechnology sector in the United States is witnessing a surge […]

The FDA’s decision is planned for June 2024, and follows the successful results of the BOREAS and NOTUS trials.

Results from the phase 3 trial showed seladelpar elicited biochemical response, normalized alkaline phosphatase, and reduced pruritus at a greater rate than placebo.

Robert Wood, MD, discusses how the FDA approval of omalizumab (Xolair) changes the management of pediatric food allergy and what type of hurdles to optimal uptake the community may encounter.

The Food and Drug Administration granted a priority review to Krazati plus Erbitux for KRAS G12C-mutant locally advanced or metastatic colorectal cancer.

The application is supported by data from the multicohort phase 2 KRYSTAL-1 study, which evaluated adagrasib in heavily pretreated patients with KRASG12C-mutated advanced CRC.